Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?

European journal of heart failure·2017
Same author

Health-Related Quality of Life Outcomes in PARADIGM-HF.

Circulation. Heart failure·2017
Same author

Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits.

JACC. Heart failure·2017
Same author

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

Kidney international·2017
Same author

Declining Risk of Sudden Death in Heart Failure.

The New England journal of medicine·2017
Same author

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

JACC. Heart failure·2017
Same journal

A high proportion of children with severe cardiomyopathies show both myocarditis and genetic predispositions.

European journal of heart failure·2026
Same journal

Correction to: Association of patient-centred remote monitoring with clinical outcomes in patients with prior hospitalization: the TELESAT PRIOR-HF study.

European journal of heart failure·2026
Same journal

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026
Same journal

"Reply to Murthy et al. regarding AI-derived LVOT-VTI for monitoring disease progression in transthyretin cardiac amyloidosis".

European journal of heart failure·2026
Same journal

High serum transthyretin concentrations identify a low likelihood of advanced myocardial amyloid burden in suspected ATTR cardiomyopathy.

European journal of heart failure·2026
Same journal

Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial.

European journal of heart failure·2026
See all related articles

Related Experiment Video

Updated: Feb 3, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Redefining heart failure phenotypes based on ejection fraction

Ross T Campbell1, Mark C Petrie1,2, John J V McMurray1

  • 1BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK.

European Journal of Heart Failure
|October 18, 2018
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Related Experiment Videos

Last Updated: Feb 3, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K